fatty liver disease
-
MedCity Influencers, Devices & Diagnostics
A Liver Scan on the Drive-Thru Menu? It Probably Should Be.
Non-invasive liver tests provide an accessible means for healthcare providers to monitor the positive effects of patient lifestyle changes over time, reinforcing the positive behaviors that lead to improved liver health – halting or even reversing the progression of liver disease
-
Madrigal Drug Meets FDA’s Twin Goals for NASH, Paving Way for FDA Filing
A Madrigal Pharmaceuticals drug for the fatty liver disease NASH has data from a pivotal clinical trial showing improvements in the organ. Based on those results, which sent Madrigal’s stock price soaring more than 200%, the biotech is planning to seek what could become the first regulatory approval of a therapy for this metabolic disorder.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Metabolic disorder biotech Akero achieves key clinical trial win in liver disease NASH
Akero Therapeutics’ experimental NASH drug, efruxifermin, met the main and secondary goals of Phase 2b clinical trial. The biotech will still need to show that the drug’s efficacy can hold up in a pivotal study, but the results so far are a positive sign for the NASH field, which has been marred by clinical trial failures.
-
GSK joins NASH chase, paying $120M up front for rights to Arrowhead RNAi drug
GlaxoSmithKline sees enough promise in the early clinical data of a novel NASH drug to pay its developer, Arrowhead Pharmaceuticals, $120 million up front for rights to the experimental therapy. The Arrowhead drug uses RNA interference to “silence” an enzyme associated with the progression of the fatty liver disease.
-
FDA turns down Intercept’s long-anticipated NASH drug
The FDA has requested additional data from the company’s clinical trial. Intercept’s CEO expressed disappointment at the decision, saying the agency had not communicated that the drug, obeticholic acid, was not approvable.
-
Intercept hits regulatory snag at FDA, likely delaying NASH drug’s approval
The company said that the agency had requested additional data for obeticholic acid and thus pushed the upcoming advisory committee meeting back from June 9, thereby delaying its decision on approval, which had also been scheduled for June 26.
-
Genfit’s drug flops in Phase III, joining graveyard of NASH failures
The French drugmaker said Monday that its Phase III study of elafibranor failed to meet its primary and key secondary endpoints. Analysts remarked that this extends the lead of the drug likely to get the first NASH approval, Intercept’s obeticholic acid.
-
Genfit scores seventh positive data safety monitoring board opinion for Phase III NASH trial
In a note to investors, an analyst wrote that the news bodes well for the company’s anticipated Phase III readout for the drug, elafibranor. Another company, Intercept Pharmaceuticals, said the FDA had accepted its application for its investigational NASH drug, obeticholic acid.
-
Artificial Intelligence, BioPharma
Gilead, Insitro in $250M machine learning partnership to develop NASH drugs
The deal comes days after Gilead partnered on clinical development in NASH with Denmark’s Novo Nordisk, and two months after the high-profile failure of a Phase III study in the disease.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Genfit, developing drugs for NASH, to trade on Nasdaq
The company, one of several developing drugs for the growing fatty liver disease, said in an SEC filing that it would sell its shares at $26.33 apiece.
-
Intercept could score first NASH drug approval on positive Phase III data
Shares of the New York-based company jumped nearly 20 percent Tuesday on news that the REGENERATE study of obeticholic acid showed strong improvement in NASH-related liver fibrosis.
-
Gilead shares sink as NASH drug flunks Phase III study
The company said a Phase III study of selonsertib had failed, sending shares down 4 percent and feeding analyst pessimism on another Phase III study of the drug in patients with less advanced disease.
-
Report: NASH market to increase forty-fold by 2026
A new report by GlobalData has underscored the extreme blockbuster potential of fatty liver disease and non-alcoholic steatohepatitis (NASH), projecting that the current $618 million market will balloon to $25.3 billion by 2026.
-
Fatty liver disease and sleep apnea more connected than previously thought
The build up of fat in the liver and sleep apnea appear now to be […]
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
